Bruker Corp. has acquired Canopy Biosciences, a specialist in high multiplex biomarker imaging for immunology, immune-oncology, and cell therapy. The acquisition expands Bruker’s offerings in targeted multiomics and fluorescence-based imaging techniques. Financial details of the transaction have not been disclosed. Bruker also recently announced the appointment of Bonnie H. Anderson to its board of directors.